Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...

Barbara Burtness, MD highlights key news in head and neck cancer from ESMO 2025, including CAMORAL, ASPEN-03 & -04, OrigAMI-4 & -05 results.

Keytruda is approved for resectable locally advanced head and neck squamous cell carcinoma with PD-L1 expression, marking a significant advancement in treatment options. The KEYNOTE-689 trial showed a ...

Enfortumab vedotin and pembrolizumab showed a 39% overall response rate in recurrent/metastatic HNSCC with PD-L1 CPS ≥1. The trial reported a 9.8% complete response rate and a 29.3% partial response ...